Literature DB >> 207733

Contributions of plasma triiodothyronine and local thyroxine monodeiodination to triiodothyronine to nuclear triiodothyronine receptor saturation in pituitary, liver, and kidney of hypothyroid rats. Further evidence relating saturation of pituitary nuclear triiodothyronine receptors and the acute inhibition of thyroid-stimulating hormone release.

J E Silva, P R Larsen.   

Abstract

Injections of triiodothyronine (T(3)) and thyroxine (T(4)) into chronically hypothyroid rats were used to evaluate the contribution of intracellular T(4) to T(3) conversion to nuclear T(3) in pituitary, liver, and kidney, and to correlate the occupancy of pituitary nuclear T(3) receptors with inhibition of thyroid-stimulating hormone (TSH) release. Injection of a combination of 70 ng T(3) and 400 ng T(4)/100 g body wt resulted in plasma T(3) concentrations of 45+/-7 ng/dl (mean+/-SD) and 3.0+/-0.4 mug/dl T(4) 3 h later. At that plasma T(3) level, the contribution of plasma T(3) to the nuclear receptor sites resulted in saturation of 34+/-7% for pituitary, 27+/-5% for liver, and 33+/-2% for kidney. In addition to the T(3) derived from plasma T(3), there was additional T(3) derived from intracellular monodeiodination of T(4) in all three tissues that resulted in total nuclear occupancy (as percent saturation) of 58+/-11% (pituitary), 36+/-8% (liver), and 41+/-11% (kidney), respectively. The percent contribution of T(3) derived from cellular T(4) added 41% of the total nuclear T(3) in the pituitary which was significantly higher than the contribution of this source in the liver (24%) or the kidney (19%). 3 h after intravenous injection of increasing doses of T(3), the plasma T(3) concentration correlated well with both the change in TSH and the nuclear occupancy, suggesting a linear relationship between the integrated nuclear occupancy by T(3) and TSH release rate. The contribution of intrapituitary T(4) to T(3) conversion to nuclear T(3) was accompanied by an appropriate decrease in TSH, supporting the biological relevance of nuclear T(3). Pretreatment of the animals with 6-n-propylthiouracil before T(4) injection decreased neither the nuclear T(3) derived from intrapituitary T(4) nor the subsequent decrease in TSH. These results indicate that intracellular monodeiodination of T(4) contributes substantially to the nuclear T(3) in the pituitary of the hypothyroid rat, and suggest a linear inverse relationship between nuclear receptor occupancy by T(3) in the pituitary and TSH release rate. The data further indicate that T(4) to T(3) monodeiodination is considerably more important as a source of nuclear T(3) in the pituitary than in the liver and kidney. This provides a mechanism whereby the TSH secretion could respond promptly to a decrease in thyroid secretion (predominantly T(4)) before a decrease in plasma T(3) would be expected to lead to significant metabolic hypothyroidism.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 207733      PMCID: PMC372646          DOI: 10.1172/JCI109041

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Thyroid hormone action. Demonstration of similar receptors in isolated nuclei of rat liver and cultured GH1 cells.

Authors:  H H Samuels; J S Tsai
Journal:  J Clin Invest       Date:  1974-02       Impact factor: 14.808

2.  In vivo deiodination of labeled L-thyroxine to L-3,5,3'-triiodothyronine in mouse and human pituitaries.

Authors:  R GRINBERG; E M VOLPERT; S C WERNER
Journal:  J Clin Endocrinol Metab       Date:  1963-02       Impact factor: 5.958

3.  Inhibition of the biological action of thyroid hormones by actinomycin D and puromycin.

Authors:  J R TATA
Journal:  Nature       Date:  1963-03-23       Impact factor: 49.962

4.  The metabolism of 1131-labelled thyroid hormones in the hypophysis and brain of the rabbit.

Authors:  D H FORD; J GROSS
Journal:  Endocrinology       Date:  1958-04       Impact factor: 4.736

5.  A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid.

Authors:  K BURTON
Journal:  Biochem J       Date:  1956-02       Impact factor: 3.857

6.  A study of extrathyroidal conversion of thyroxine (T4) to 3,3',5-triiodothyronine (T3) in vitro.

Authors:  I J Chopra
Journal:  Endocrinology       Date:  1977-08       Impact factor: 4.736

7.  Pituitary nuclear 3,5,3'-triiodothyronine and thyrotropin secretion: an explanation for the effect of thyroxine.

Authors:  J E Silva; P R Larsen
Journal:  Science       Date:  1977-11-11       Impact factor: 47.728

8.  Stimulation of hepatic mitochondrial alpha-glycerophosphate dehydrogenase and malic enzyme by L-triiodothyronine. Characteristics of the response with specific nuclear thyroid hormone binding sites fully saturated.

Authors:  J H Oppenheimer; E Silva; H L Schwartz; M I Surks
Journal:  J Clin Invest       Date:  1977-03       Impact factor: 14.808

9.  Isolation of labeled triiodothyronine from serum using affinity chromatography: application to the extimation of the peripheral T4 to T3 conversion in rats.

Authors:  C J Zimmerman; M Izumi; P R Larsen
Journal:  Metabolism       Date:  1978-03       Impact factor: 8.694

10.  Studies with mouse pituitary thyrotropic tumors. IV. Presence of 3,5,3'-triiodothyronine in certain mouse pituitary tumors after the injection of labeled L-thyroxine.

Authors:  E M VOLPERT; R GRINBERG; S C WERNER
Journal:  Endocrinology       Date:  1962-09       Impact factor: 4.736

View more
  51 in total

1.  Plasma concentrations of free triiodothyronine predict weight change in euthyroid persons.

Authors:  Emilio Ortega; Nicola Pannacciulli; Clifton Bogardus; Jonathan Krakoff
Journal:  Am J Clin Nutr       Date:  2007-02       Impact factor: 7.045

Review 2.  Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling.

Authors:  Balázs Gereben; Ann Marie Zavacki; Scott Ribich; Brian W Kim; Stephen A Huang; Warner S Simonides; Anikó Zeöld; Antonio C Bianco
Journal:  Endocr Rev       Date:  2008-09-24       Impact factor: 19.871

3.  Effects of substitution and high-dose thyroid hormone therapy on deiodination, sulfoconjugation, and tissue thyroid hormone levels in prolonged critically ill rabbits.

Authors:  Yves Debaveye; Björn Ellger; Liese Mebis; Theo J Visser; Veerle M Darras; Greet Van den Berghe
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

Review 4.  Paradigms of Dynamic Control of Thyroid Hormone Signaling.

Authors:  Antonio C Bianco; Alexandra Dumitrescu; Balázs Gereben; Miriam O Ribeiro; Tatiana L Fonseca; Gustavo W Fernandes; Barbara M L C Bocco
Journal:  Endocr Rev       Date:  2019-08-01       Impact factor: 19.871

5.  Comparative study of pituitary-thyroid hormone economy in fasting and hypothyroid rats.

Authors:  D L St Germain; V A Galton
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

6.  Relationship between the accumulation of pituitary growth hormone and nuclear occupancy by triiodothyronine in the rat.

Authors:  P Coulombe; H L Schwartz; J H Oppenheimer
Journal:  J Clin Invest       Date:  1978-11       Impact factor: 14.808

7.  Kinetic evidence suggesting two mechanisms for iodothyronine 5'-deiodination in rat cerebral cortex.

Authors:  T J Visser; J L Leonard; M M Kaplan; P R Larsen
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

8.  A rat model of the 131I-induced changes in thyroid function.

Authors:  C P Reilly; R G Symons; M L Wellby
Journal:  J Endocrinol Invest       Date:  1986-10       Impact factor: 4.256

9.  Physiological and genetic analyses of inbred mouse strains with a type I iodothyronine 5' deiodinase deficiency.

Authors:  M J Berry; D Grieco; B A Taylor; A L Maia; J D Kieffer; W Beamer; E Glover; A Poland; P R Larsen
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

10.  Evidence for two tissue-specific pathways for in vivo thyroxine 5'-deiodination in the rat.

Authors:  J E Silva; J L Leonard; F R Crantz; P R Larsen
Journal:  J Clin Invest       Date:  1982-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.